DK2593792T3 - Proteinbindingsdomæner, der stabiliserer funktionelle konformationelle tilstande af GPCR'er og anvendelser deraf - Google Patents

Proteinbindingsdomæner, der stabiliserer funktionelle konformationelle tilstande af GPCR'er og anvendelser deraf Download PDF

Info

Publication number
DK2593792T3
DK2593792T3 DK11734078.6T DK11734078T DK2593792T3 DK 2593792 T3 DK2593792 T3 DK 2593792T3 DK 11734078 T DK11734078 T DK 11734078T DK 2593792 T3 DK2593792 T3 DK 2593792T3
Authority
DK
Denmark
Prior art keywords
gpcrs
applications
binding domains
protein binding
conformational states
Prior art date
Application number
DK11734078.6T
Other languages
English (en)
Inventor
Jan Steyaert
Els Pardon
Toon Laeremans
Juan Fung
Brian Kobilka
Søren Rasmussen
Original Assignee
Vib Vzw
Univ Brussel Vrije
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Univ Brussel Vrije, Univ Leland Stanford Junior filed Critical Vib Vzw
Application granted granted Critical
Publication of DK2593792T3 publication Critical patent/DK2593792T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
DK11734078.6T 2010-07-16 2011-07-18 Proteinbindingsdomæner, der stabiliserer funktionelle konformationelle tilstande af GPCR'er og anvendelser deraf DK2593792T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39978110P 2010-07-16 2010-07-16
GBGB1014715.5A GB201014715D0 (en) 2010-09-06 2010-09-06 Nanobodies stabilizing functional conformational states of GPCRS
PCT/EP2011/062287 WO2012007593A1 (en) 2010-07-16 2011-07-18 Protein binding domains stabilizing functional conformational states of gpcrs and uses thereof

Publications (1)

Publication Number Publication Date
DK2593792T3 true DK2593792T3 (da) 2020-02-03

Family

ID=43037319

Family Applications (4)

Application Number Title Priority Date Filing Date
DK11732498.8T DK2593791T3 (da) 2010-07-16 2011-07-18 Proteinbindingsdomæner, som stabiliserer funktionelle konformationstilstande af GPCR, og anvendelser deraf
DK11734078.6T DK2593792T3 (da) 2010-07-16 2011-07-18 Proteinbindingsdomæner, der stabiliserer funktionelle konformationelle tilstande af GPCR'er og anvendelser deraf
DK19169005.6T DK3557255T3 (da) 2010-07-16 2011-07-18 Proteinbindingsdomæner, der stabiliserer funktionelle konformationelle tilstande af GPCR'er, og anvendelser deraf
DK19169004.9T DK3557254T3 (da) 2010-07-16 2011-07-18 Proteinbindingsdomæner, der stabiliserer funktionelle konformationelle tilstande af GPCR'er, og anvendelser deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11732498.8T DK2593791T3 (da) 2010-07-16 2011-07-18 Proteinbindingsdomæner, som stabiliserer funktionelle konformationstilstande af GPCR, og anvendelser deraf

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK19169005.6T DK3557255T3 (da) 2010-07-16 2011-07-18 Proteinbindingsdomæner, der stabiliserer funktionelle konformationelle tilstande af GPCR'er, og anvendelser deraf
DK19169004.9T DK3557254T3 (da) 2010-07-16 2011-07-18 Proteinbindingsdomæner, der stabiliserer funktionelle konformationelle tilstande af GPCR'er, og anvendelser deraf

Country Status (14)

Country Link
US (16) US20130137856A1 (da)
EP (7) EP2593792B1 (da)
JP (4) JP6302248B2 (da)
CN (1) CN103180734B (da)
BR (1) BR112013001180B1 (da)
CA (1) CA2805560C (da)
DK (4) DK2593791T3 (da)
ES (4) ES2905455T3 (da)
GB (1) GB201014715D0 (da)
HR (3) HRP20220326T1 (da)
HU (1) HUE031572T2 (da)
PL (4) PL3557255T3 (da)
PT (4) PT3557255T (da)
WO (2) WO2012007593A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
EP2723764B1 (en) * 2011-06-21 2017-12-27 Vib Vzw Binding domains directed against gpcr: g protein complexes and uses derived thereof
ES2656972T3 (es) 2012-02-23 2018-03-01 Vanderbilt University Análogos de 5-aminotieno [2,3-c] piridazin-6-carboxamida como moduladores alostéricos positivos del receptor de acetilcolina muscarínico M4
CN103509115B (zh) * 2012-06-21 2016-03-23 中国科学院上海生命科学研究院 人胱抑素c纳米抗体及其应用
WO2014001557A1 (en) 2012-06-28 2014-01-03 Ucb Pharma S.A. A method for identifying compounds of therapeutic interest
WO2014035829A1 (en) * 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
DK2951201T3 (da) * 2013-01-30 2018-01-08 Vib Vzw Hidtil ukendte kimære polypeptider til screenings- og lægemiddeldetektionsformål
WO2014124020A1 (en) 2013-02-05 2014-08-14 The Board Of Trustees Of The Leland Stanford Junior University Method for selecting agents that bind to transmembrane receptors in a conformationally-selective manner
AU2014214054B2 (en) * 2013-02-05 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Muscarinic acetylcholine receptor binding agents and uses thereof
WO2014153044A1 (en) * 2013-03-14 2014-09-25 Temple University Of The Commonwealth System Of Higher Education Treatment of patients with hyponatremia and cardiac disease
ES2791068T3 (es) 2013-06-28 2020-10-30 X Body Inc Descubrimiento de antígenos objetivo, cribados fenotípicos y uso de los mismos para la identificación de epítopos objetivo específicos de células objetivo
WO2015027214A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
CN103454413B (zh) * 2013-09-04 2015-03-11 吉日木图 双峰驼特异性抗体制备及免疫检测方法
CA2924879C (en) 2013-09-23 2023-01-10 X-Body, Inc. Methods and compositions for generation of binding agents against cell surface antigens
CA2955554C (en) 2014-07-22 2022-07-05 Vib Vzw Methods to select for agents that stabilize protein complexes
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
DE102016116391B3 (de) * 2016-09-01 2018-02-01 Gea Mechanical Equipment Gmbh Verfahren zum Überwachen einer Schneckenzentrifuge
WO2018208877A1 (en) * 2017-05-09 2018-11-15 Yale University Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction
AU2018266393A1 (en) * 2017-05-12 2019-12-19 Riken Class A GPCR-binding compound modifier
CN107423555B (zh) * 2017-06-09 2020-06-30 王�忠 一种探索药物新适应症的方法
WO2019032661A1 (en) * 2017-08-09 2019-02-14 Orionis Biosciences Inc. CD8 LIAISON AGENTS
CN113501881B (zh) * 2017-09-27 2023-07-28 北京大学 融合蛋白
EP3691684A1 (en) * 2017-10-02 2020-08-12 VIB vzw Compounds to inhibit bacterial s-layer protein assembly
US11873347B2 (en) 2017-10-31 2024-01-16 Vib Vzw Antigen-binding chimeric proteins and methods and uses thereof
KR102485253B1 (ko) * 2017-11-10 2023-01-06 현대자동차주식회사 대화 시스템 및 그 제어방법
CN110759998A (zh) * 2018-07-27 2020-02-07 深圳康体生命科技有限公司 一种gfp抗体制备方法及其dna序列
SG11202111830UA (en) 2019-04-29 2021-11-29 Confo Therapeutics N V Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs
WO2020226907A1 (en) * 2019-05-07 2020-11-12 Beijing Neoletix Biological Technology Co., Ltd. Fusion protein of single domain antibody and procoagulant
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
AU2021223787A1 (en) 2020-02-21 2022-10-13 Sanofi Foreign Participations BV Propionibacterium acnes prophylactic and therapeutic immune treatment
WO2021243005A2 (en) * 2020-05-28 2021-12-02 The Board Of Trustees Of The Leland Stanford Junior University Aerosolized mucus-tethering nanobodies to protect against viral and microbial contamination in closed and semi-enclosed spaces
US20230391861A1 (en) * 2020-09-25 2023-12-07 Philip A. Beachy Potent binding agents for activation of the hedgehog signaling pathway
CN112843222B (zh) * 2021-01-21 2023-01-31 暨南大学 Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用
CN112851811B (zh) * 2021-01-28 2022-08-09 姜国胜 一种cd44v6纳米抗体及其作为白血病研究试剂的应用
WO2022258437A1 (en) * 2021-06-07 2022-12-15 Paul Scherrer Institut Quantification of protein-protein interaction of membrane proteins using high-mass mass spectrometry
CN113717874B (zh) * 2021-09-27 2023-04-11 四川大学 一种耐高温、耐高糖的酿酒酵母菌株及其构建方法和应用
WO2023168429A2 (en) * 2022-03-04 2023-09-07 Coagulant Therapeutics Corporation Camelid antibodies against activated protein c and uses thereof
WO2023201173A2 (en) * 2022-04-11 2023-10-19 Vanderbilt University Anti-cox-2 nanobodies for endoscopic visualization of colorectal adenomas
CN116813781B (zh) * 2023-07-29 2024-01-12 十堰市太和医院（湖北医药学院附属医院） 一种靶向β2AR的纳米抗体及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE188248T1 (de) 1988-10-03 2000-01-15 Scripps Research Inst Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen auf liganden, die an proteine der cytoadhesin-superfamilie binden
JP2937474B2 (ja) * 1988-10-03 1999-08-23 スクリップス クリニック アンド リサーチ ファウンデーション レセプター誘導結合部位に対するモノクローナル抗体
DK1087013T3 (da) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobuliner uden lette kæder
EP1051493A2 (en) 1998-01-26 2000-11-15 Unilever Plc Method for producing antibody fragments
AU2291700A (en) 1999-01-19 2000-08-07 Unilever Plc Method for producing antibody fragments
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US7208279B2 (en) 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
US20020192711A1 (en) * 2001-04-20 2002-12-19 Nestor John J. Methods for identifying ligands of G-Protein-Coupled receptors
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20030129649A1 (en) 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
WO2004035614A1 (en) * 2001-07-11 2004-04-29 Karo Bio Ab Synthetic or partially purified peptides which can bind to specific subunits of g proteins and uses thereof
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
WO2006086883A1 (en) 2005-02-16 2006-08-24 Universite De Montreal Biosensors for monitoring receptor-mediated g-protein activation
US8076090B2 (en) * 2005-04-05 2011-12-13 Corning Incorporated Label free biosensors and cells
AU2006301426A1 (en) 2005-10-11 2007-04-19 Ablynx N.V. NanobodiesTM and polypeptides against EGFR and IGF-IR
WO2007096142A2 (en) * 2006-02-22 2007-08-30 Philogen Spa Vascular tumor markers
EP2557090A3 (en) * 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
ATE544854T1 (de) * 2007-03-22 2012-02-15 Heptares Therapeutics Ltd Mutante g-protein-gekoppelte rezeptoren und selektionsverfahren dafür
WO2008138536A2 (en) * 2007-05-15 2008-11-20 F. Hoffmann-La Roche Ag Antibody directed to g protein coupled receptors (gpcr)
WO2009051633A1 (en) 2007-10-15 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Gpcr crystalization method using an antibody
GB0724860D0 (en) * 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
US9212226B2 (en) * 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
DK2285408T3 (da) * 2008-06-05 2019-02-04 Ablynx Nv Aminosyresekvenser rettet mod kappeproteiner i et virus og polypeptider, der omfatter disse, til behandling af virussygdomme
US20110166076A1 (en) * 2008-09-10 2011-07-07 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
AU2009326075B2 (en) 2008-12-08 2014-06-05 Complix Nv Single-chain antiparallel coiled coil proteins
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
EP2723764B1 (en) 2011-06-21 2017-12-27 Vib Vzw Binding domains directed against gpcr: g protein complexes and uses derived thereof
AU2014214054B2 (en) 2013-02-05 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Muscarinic acetylcholine receptor binding agents and uses thereof
EP3099707B1 (en) 2014-01-30 2021-12-29 Vib Vzw Opioid receptor binding agents and uses thereof

Also Published As

Publication number Publication date
CN103180734A (zh) 2013-06-26
AU2011278244B8 (en) 2016-02-11
EP3557257A1 (en) 2019-10-23
US9689872B2 (en) 2017-06-27
PL2593792T3 (pl) 2020-05-18
US20240103013A1 (en) 2024-03-28
GB201014715D0 (en) 2010-10-20
BR112013001180B1 (pt) 2022-01-11
DK3557254T3 (da) 2022-01-24
US20180100865A1 (en) 2018-04-12
HRP20170201T1 (hr) 2017-04-07
US20220099683A1 (en) 2022-03-31
EP2593791B1 (en) 2016-11-23
PT2593791T (pt) 2017-02-01
US20190383829A1 (en) 2019-12-19
PT3557254T (pt) 2022-01-20
AU2011278244B2 (en) 2016-01-28
US10054598B2 (en) 2018-08-21
JP2013536173A (ja) 2013-09-19
WO2012007593A1 (en) 2012-01-19
US20200025773A1 (en) 2020-01-23
JP6302248B2 (ja) 2018-03-28
US20190383827A1 (en) 2019-12-19
EP2593791A1 (en) 2013-05-22
US20160347842A1 (en) 2016-12-01
US20190049463A1 (en) 2019-02-14
HRP20220326T1 (hr) 2022-05-13
JP2023085340A (ja) 2023-06-20
EP3557254A1 (en) 2019-10-23
CA2805560C (en) 2019-10-29
HRP20220204T1 (hr) 2022-04-29
CN103180734B (zh) 2016-03-02
EP2593792A1 (en) 2013-05-22
EP4273549A1 (en) 2023-11-08
BR112013001180A2 (pt) 2016-05-31
PL2593791T3 (pl) 2017-08-31
US9863959B2 (en) 2018-01-09
US20130183287A1 (en) 2013-07-18
ES2905455T3 (es) 2022-04-08
JP2018027936A (ja) 2018-02-22
US20180067126A1 (en) 2018-03-08
PT2593792T (pt) 2020-01-29
ES2907049T3 (es) 2022-04-21
JP2021042209A (ja) 2021-03-18
US20190383828A1 (en) 2019-12-19
US20170153245A1 (en) 2017-06-01
AU2011278244A8 (en) 2016-02-11
PL3557255T3 (pl) 2022-06-20
US20130137856A1 (en) 2013-05-30
US11162954B2 (en) 2021-11-02
PL3557254T3 (pl) 2022-05-23
EP3557255B1 (en) 2021-11-17
WO2012007594A1 (en) 2012-01-19
HUE031572T2 (en) 2017-07-28
US20190041400A1 (en) 2019-02-07
EP3557256A1 (en) 2019-10-23
ES2613532T3 (es) 2017-05-24
US20190383826A1 (en) 2019-12-19
DK2593791T3 (da) 2017-02-06
EP3557255A1 (en) 2019-10-23
US9453065B2 (en) 2016-09-27
ES2771479T3 (es) 2020-07-06
US10078088B2 (en) 2018-09-18
PT3557255T (pt) 2022-01-20
US11162953B2 (en) 2021-11-02
CA2805560A1 (en) 2012-01-19
JP6859229B2 (ja) 2021-04-14
JP7248637B2 (ja) 2023-03-29
EP3557254B1 (en) 2021-12-15
US20190383825A1 (en) 2019-12-19
DK3557255T3 (da) 2022-01-24
EP2593792B1 (en) 2019-11-13
US10436796B2 (en) 2019-10-08
AU2011278244A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
DK2593792T3 (da) Proteinbindingsdomæner, der stabiliserer funktionelle konformationelle tilstande af GPCR'er og anvendelser deraf
LTC2379594I2 (lt) Žmogaus CGRP receptorių rišantys antikūnai
SMT201600335B (it) Proteine leganti eterodimeri e loro usi
DK2913344T3 (da) Specifikke bindingsproteiner og anvendelser deraf
DK3168229T3 (da) Fremstilling af proteiner og polypeptider.
HK1217511A1 (zh) 包含 結構域的結合蛋白
DK3199547T3 (da) Antistoflignende bindingsproteiner med dobbelt variabel region og overkrydsende orientering af bindingsregion
DK2276352T3 (da) Proteinkoncentrat af stivelsesholdigt korn: sammensætning, fremgangsmåde til fremstilling og anvendelser deraf
DK3275899T3 (da) Optimering af antistoffer, der binder lymfocytaktiveringsgen-3 (lag-3), og anvendelser deraf
DK3091034T3 (da) Anti-CD40-antistoffer og anvendelser deraf
DK3418300T3 (da) Neutralisering af anti-influenza-a-virusantistoffer og anvendelser deraf
EP2426557A4 (en) Light-sensitive modified polyimide resin composition and use
DK3150586T3 (da) Modulatorer af farmakokinetiske egenskaber af terapeutika
DK2352756T3 (da) Højaffin T-cellereceptor og anvendelse af denne
DK2594567T3 (da) Heterocykliske alkynylbenzenforbindelser og anvendelser deraf
DK2142529T3 (da) Trpv1-antagonister og anvendelser deraf
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
DK2917229T3 (da) Antistoffer og fragmenter, der er mod alfa-3-domænerne af hla-g-protein, fremgangsmåder og midler til deres forberedelse, og anvendelsen deraf
DK2124999T3 (da) Activin-actrii antagonister og anvendelser til behandling af anæmi
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2240203T3 (da) Alfa5-beta1-antistoffer og deres anvendelser
DK2513193T3 (da) Forbedrede blends af polyarylenethere og polyarylensulfider
DK2352509T3 (da) Hla-g-proteiner og farmaceutiske anvendelser deraf
DK2531181T3 (da) Formuleringer af rasagilin med forlænget afgivelse og anvendelser deraf
DK2260873T3 (da) Pcylering af proteiner